menu
    • menu
    [{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-GBA1","moa":"GBA1","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ABL Bio"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coave Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Coave Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coave Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Coave Therapeutics \/ Seroba Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Seroba Life Sciences"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Institute of Neurodegenerative Diseases of Bordeaux","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux"}]

    Find Clinical Drug Pipeline Developments & Deals by Coave Therapeutics

    Menu

    Coave Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Coave Secures €32M Series A to Advance Genetic Medicine Pipeline

                            Details : The funding will also enable Coave to advance its lead preclinical assets toward clinical development of CTx-TFEB. It is being evaluated for treating Amyotrophic Lateral Sclerosis.

                            Product Name : CTx-TFEB

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            eyeDNA to Present Follow-up Data on Gene Therapy HORA-PDE6b for Retinitis at ARVO 2024

                            Details : Coave lead program HCTx-PDE6b (AAV2/5-hPDE6B), an AAV5-based gene replacement therapy, is being evaluated in a Phase I/II trial for the treatment of retinitis pigmentosa.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $2.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Coave Therapeutics Receives Grant from Als Association for CTx-Tfeb Program

                            Details : The funding will support Coave in developing CTx-TFEB, which is being evaluated in preclinical studies for multiple system atrophy treatment.

                            Product Name : CTx-TFEB

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $2.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Pa...

                            Details : CTx-PDE6b is a clinical stage AAV5-based gene therapy for the treatment of retinitis pigmentosa (RP) caused by bi-allelic mutations of the PDE6b gene. There are currently no approved treatments for PDE6b RP.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 31, 2023

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Institute of Neurodegenerative Diseases of Bordeaux

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to D...

                            Details : The collaboration will explore the development of gene therapy product CTx-TFEB, targeting the transcription factor EB (TFEB) for the treatment of alpha-synucleinopathies, such as Multiple System Atrophy (MSA) and idiopathic Parkinson’s disease (PD).

                            Product Name : CTx-TFEB

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 14, 2022

                            Lead Product(s) : CTx-TFEB

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Institute of Neurodegenerative Diseases of Bordeaux

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Coave Therapeutics and ABL Enter Into Strategic Collaboration to Develop Gene Therapy Manufacturing Processes ...

                            Details : Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products including CTx-GBA1.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Laboratoires Thea

                            Deal Size : $87.3 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coave Therapeutics and Théa Open Innovation Sign Exclusive Licensing, Co-Development and Commercialization Ag...

                            Details : Coave and Théa will co-develop CTx-PDE6b under the joint agreement. Coave retains rights to commercialize CTx-PDE6b in the US and Théa receives an exclusive license to commercialize CTx-PDE6b in Europe (EU27), Ukraine, Turkey, Russia and North Africa.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $11.6 million

                            September 16, 2021

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Laboratoires Thea

                            Deal Size : $87.3 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Coave Therapeutics

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Seroba Life Sciences

                            Deal Size : $39.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Coave Therapeutics Closes $39 million Series B Financing to Develop its Gene Therapy Pipeline and Next-Generat...

                            Details : Coave Therapeutics will use the proceeds to support: its lead clinical program CTx-PDE6b; Developing its AAV Ligand Conjugate platform; Developing its AAV Ligand Conjugate (‘ALIGATER’) platform; Partnerships in key disease areas to progress novel coA...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 21, 2021

                            Lead Product(s) : CTx-PDE6b

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Seroba Life Sciences

                            Deal Size : $39.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth